RxDoctor Payments Data

Angela Hale, MD

Psychiatry · Macon, GANPI 1881648780

Payments from drug & device makers

$6,602in general payments, 2019–2025

Across 193 payments — averaging $34.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$1K
  • AbbVie$1K
  • Otsuka America Pharmaceutical, Inc.$918
  • Teva Pharmaceuticals USA, Inc.$866
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$707
  • E.r. Squibb & Sons, L.L.C.$414
  • plus $1K from 11 others

What the payments were for

  • Food & beverage$6,37497%
  • Education$2283%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,602 in reported general payments places this provider in the 85th percentile of 900 psychiatry providers in Georgia.

See all psychiatry providers in Georgia

Medicare billing

Part B allowed, 2024
$16,941
Medicare patients
56
Services billed
334

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Austedo XrDeutetrabenazine24$161,449
AustedoDeutetrabenazine11$118,150
LybalviOlanzapine/Samidorphan Malate12$18,248
Aripiprazole79$13,358
Paliperidone ErPaliperidone66$9,849
Lisdexamfetamine Dimesylate11$2,678
Ziprasidone Hcl42$2,344
Quetiapine Fumarate156$2,068
Perphenazine13$1,830
Bupropion XlBupropion Hcl50$1,772
Bupropion Hcl SrBupropion Hcl53$1,552
Buspirone Hcl98$1,427
Lurasidone Hcl49$1,329
Duloxetine Hcl49$1,163
Lamotrigine73$871

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo Xr, Austedo$866$279,59835 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 900 psychiatry providers in Georgia.

Other psychiatry in Macon

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →